ロード中...
Profound thrombocytopenia after primary exposure to eptifibatide
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,00...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108691/ https://ncbi.nlm.nih.gov/pubmed/21701628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S13239 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|